Lung Disease Therapeutics Market Size, Report 2023-2032
The global lung disease therapeutics market size was estimated at around USD 81.24 billion in 2022 and it is projected to hit around USD 146.31 billion by 2032, growing at a CAGR of 6.06% from 2023 to 2032.
Key Pointers
Report Scope of the Lung Disease Therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 81.24 billion |
| Revenue Forecast by 2032 | USD 146.31 billion |
| Growth rate from 2023 to 2032 | CAGR of 6.06% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Johnson & Johnson, Amgen Inc., AstraZeneca, Boehringer Ingelheim, Pfizer Inc., Allergan Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Novartis AG |
Lung disease therapeutics include a range of drugs and treatments used to manage various lung conditions, including asthma, COPD, lung cancer, and idiopathic pulmonary fibrosis (IPF). The market is driven by factors such as rise in aging population, increase in rate of smoking, growth in air pollution, and surge in awareness about lung diseases.
Some respiratory diseases are acute, such as an infection, and improve with treatment. Other diseases are chronic and must be managed. Chronic respiratory conditions can be caused by various lung diseases. Millions of people in the U.S. suffer from chronic respiratory diseases. Lung diseases are classified into specific conditions; hence, it is difficult to estimate how many people suffer from them.
Asthma is the largest segment of the lung disease therapeutics market, due to its high prevalence and the need for ongoing treatment and management. Asthma affects 24.83 million people in the U.S., including 5.54 million children, and is responsible for millions of emergency department visits and tens of billions of dollars in healthcare costs each year.
Disease Type Insights
In terms of disease type, the asthma segment accounted for significant global lung disease therapeutics market share in 2022. Asthma is a chronic lung disease that affects the airways, making it difficult to breathe. It is characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and shortness of breath.
High prevalence and the need for ongoing treatment & management can be ascribed to the large market share of the segment. Different types of medication, including inhaled corticosteroids, beta-agonists, and leukotriene modifiers, are used to manage asthma symptoms and prevent exacerbations.
Drug Class Insights
Based on drug class, the corticosteroids segment led the global lung disease therapeutics market in 2022. Corticosteroids are a class of drugs commonly used to treat lung diseases such as asthma and COPD. These drugs reduce inflammation in the airways, which helps improve breathing.
High effectiveness can be ascribed to the corticosteroids segment’s significant share of the lung disease therapeutics market. These drugs are widely used in the treatment of various lung diseases and have been proven to be safe and effective. Therefore, they are often prescribed as first-line therapy for several lung diseases.
The bronchodilators segment held the second-largest share of the market in 2022. Bronchodilator is a type of medication that makes breathing easier. It relaxes the muscles in the lungs and widens the airways. This drug class is used to treat long-term conditions such as asthma and COPD.
Distribution Channel Insights
In terms of distribution channel, the hospital pharmacies segment dominated the global lung disease therapeutics industry in 2022. Hospital pharmacies are responsible for supplying and dispensing medications to inpatients. Thus, they play a critical role in the management of lung diseases such as COPD and asthma.
Hospital pharmacies have access to a range of medications, including specialized therapeutics for lung diseases. These pharmacies are staffed by trained pharmacists who provide expert advice on medication usage and management. Hospital pharmacies are closely connected to other healthcare professionals such as doctors and nurses, leading to better coordination of care and improved patient outcomes.
Hospital pharmacies have the infrastructure and resources to handle complex medication regimens and manage potential drug interactions or adverse reactions. They also play a key role in monitoring and managing the usage of antibiotics, which are often prescribed for lung infection treatment.
Regional Insights
North America accounted for the largest share in 2022. The region has a well-established market and advanced healthcare systems. Market players are making significant investments in research & development activities in the region. Furthermore, high prevalence of lung diseases, such as COPD and asthma, is driving market statistics in North America.
Emerging markets in Asia Pacific and Latin America have less investment in the lung disease therapeutics industry and low prevalence of lung diseases. However, these regions are likely to witness significant market development in the next few years due to improvement in healthcare systems and increase in prevalence of lung diseases.
As per lung disease therapeutics market analysis, Middle East & Africa held small share in 2022. The market in the region is expected to experience robust growth during the forecast period. This can be ascribed to the increase in efforts to improve healthcare infrastructure and rise in patient access to treatment.
Lung Disease Therapeutics Market Segmentations:
By Disease Type
By Drug Class
By Molecule Type
By Treatment Type
By Distribution Channel
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lung Disease Therapeutics Market
5.1. COVID-19 Landscape: Lung Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lung Disease Therapeutics Market, By Disease Type
8.1. Lung Disease Therapeutics Market, by Disease Type, 2023-2032
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Lung Cancer
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chronic Obstructive Pulmonary Disease (COPD)
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Lung Disease Therapeutics Market, By Drug Class
9.1. Lung Disease Therapeutics Market, by Drug Class, 2023-2032
9.1.1. Corticosteroids
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bronchodilator
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Antimicrobial
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Alkylating Agents
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Mucolytics
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Lung Disease Therapeutics Market, By Molecule Type
10.1. Lung Disease Therapeutics Market, by Molecule Type, 2023-2032
10.1.1. Small molecules
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biologics
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Lung Disease Therapeutics Market, By Treatment Type
11.1. Lung Disease Therapeutics Market, by Treatment Type, 2023-2032
11.1.1. Chemotherapy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Immunotherapy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Targeted Therapy
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Radiation Therapy
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Lung Disease Therapeutics Market, By Distribution Channel
12.1. Lung Disease Therapeutics Market, by Distribution Channel, 2023-2032
12.1.1. Online
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Hospital
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Retail
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Lung Disease Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.7. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.10. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Johnson & Johnson
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AstraZeneca
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Boehringer Ingelheim
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Allergan Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bristol-Myers Squibb Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Eli Lilly and Company
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Hoffmann-La Roche
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers